Mexico - Delayed Quote MXN

BioMarin Pharmaceutical Inc. (BMRN.MX)

1,480.00

0.00

(0.00%)

At close: March 7 at 11:20:12 AM CST

BioMarin Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations

BioMarin Pharmaceutical ( NASDAQ:BMRN ) First Quarter 2025 Results Key Financial Results Revenue: US$745.1m (up 15...

Simply Wall St. 2 days ago

BMRN
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the first quarter ended March 31, 2025.

PR Newswire 4 days ago

BMRN
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update.

PR Newswire 18 days ago

BMRN
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels in adolescents aged 12-17 with phenylketonuria (PKU) compared to diet alone. Safety results were consistent with the known profile of the medicine. PALYNZIQ is the first and only enzyme therapy approved to treat adults with PKU.

PR Newswire last month

BMRN
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO® (vosoritide) in children with achondroplasia and in ongoing clinical trials investigating other skeletal conditions, as well as PALYNZIQ® (pegvaliase-pqpz) in adults with phenylketonuria (PKU). The latest findings further validate the long-term benefit and established safety profiles of both medicines, which continue to play a pivotal role for people living with these genetically defined condit

PR Newswire last month

BMRN
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

StockStory last month

VRTX

BMRN

MRNA
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks last month

CSL.AX

BMRN
Is BioMarin Pharmaceutical (BMRN) the Best Biotech Stock According to Billionaires?

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies […]

Insider Monkey last month

BMRN
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks last month

BMRN
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.

Zacks last month

AZN

196170.KQ

BMRN
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"

BioMarin (BMRN) could produce exceptional returns because of its solid growth attributes.

Zacks last month

BMRN
Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to Trade

The consensus price target hints at a 36.6% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks last month

BMRN
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks last month

BMRN
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.

Zacks last month

PTGX

JNJ

BMRN
1 Healthcare Stock to Target This Week and 2 to Turn Down

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.8%. This performance was disappointing since the S&P 500 climbed 1%.

StockStory last month

VTRS

BMRN

PACB
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).

StockStory last month

MYGN

BMRN

MRNA
4 Discounted PEG Stocks Offering the Best Returns to Value Investors

Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.

Zacks last month

BMRN

DVN

JAZZ
Statutory Profit Doesn't Reflect How Good BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings Are

BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) just reported healthy earnings but the stock price didn't move much. Our...

Simply Wall St. 2 months ago

BMRN
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.

StockStory 2 months ago

SRPT

BMRN

ABBV
Is Auna S.A. (AUNA) Stock Outpacing Its Medical Peers This Year?

Here is how Auna S.A. (AUNA) and BioMarin Pharmaceutical (BMRN) have performed compared to their sector so far this year.

Zacks 2 months ago

AUNA

BMRN

Performance Overview

Return	BMRN.MX	S&P 500 (^GSPC)
YTD	-12.94%	-3.93%
1-Year	-5.00%	+10.19%
3-Year	-10.21%	+36.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioMarin Pharmaceutical Inc. (BMRN.MX)

BioMarin Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

Is BioMarin Pharmaceutical (BMRN) the Best Biotech Stock According to Billionaires?

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to Trade

Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

1 Healthcare Stock to Target This Week and 2 to Turn Down

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

4 Discounted PEG Stocks Offering the Best Returns to Value Investors

Statutory Profit Doesn't Reflect How Good BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings Are

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

Is Auna S.A. (AUNA) Stock Outpacing Its Medical Peers This Year?

Performance Overview